Silgan Holdings Third Quarter 2026 Earnings Call - SILGAN HOLDINGS INC

Financial Performance:

• Q3 2026 net sales were approximately $2.0 billion, a 2% increase year-over-year driven by raw material and cost pass-throughs.
• Total adjusted EBIT reached $235 million, up 6% year-over-year, primarily fueled by strong performance in the metal container segment.
• Adjusted EPS was $1.31, a 7% increase year-over-year, driven by higher EBIT and lower interest expense, partially offset by a higher adjusted tax rate.
• Full-year 2026 adjusted EPS guidance was raised twice to a new range of $3.83 to $3.93 (midpoint up 4% from prior year's $1.72).
• Confirmed free cash flow for 2026 is approximately $450 million, including estimated capital expenditures of $310 million.
• Q3 2026 adjusted EBIT for Dispensing & Specialty Closures was down $2 million year-over-year due to unrecovered inflation, expected to be recovered in H2.
• Custom containers delivered record adjusted EBIT despite an 8% volume decline, attributed to the exit of lower-margin business.

Guidance and Future Outlook:

• Q4 2026 adjusted EPS is guided to $0.76–$0.86, with volumes expected to be comparable to prior year across all segments.
• Management expects low single-digit adjusted EBIT growth and another year of organic earnings and free cash flow growth in 2027.
• Full-year 2026 volume expectations are now projected to be flat year-over-year across all three segments.
• The acquisition of Trivium is expected to close in mid-2027, with the company planning for integration and incremental investment to prepare the businesses.
• Long-term outlook remains positive for mid-single-digit growth in fragrance/beverage and double-digit growth in healthcare pharma post-transition.

Business Segments and Product Lines:

• Dispensing & Specialty Closures: Delivered mid-single-digit growth in high-end fragrance products; prescription pharma dispensing products grew double-digits in North America, becoming a ~$250M revenue stream.
• Metal Containers: Adjusted EBIT grew 10% year-over-year; growth driven by normalized demand in fruit/vegetable markets and wet pet food, offset by softer soup volumes.
• Custom Containers: Achieved record adjusted EBIT; volumes down 8% due to planned exit of lower-margin business and footprint optimization, but price/mix improvements drove profitability.
• New Business Wins: Management highlighted winning a disproportionate share of new product launches in high-end fragrance and healthcare pharma due to innovation capabilities.
• Future Structure: The proposed split will create Silgan MCC (Metal Containers & Custom) and Silgan DS (Dispensing Solutions), allowing for clearer focus on respective growth drivers.

Market and Competitive Landscape:

• Operating in a challenging consumer environment characterized by muted demand in food/beverage and home care, though pet food and fragrance remain resilient.
• Private label packaging is performing well due to consumer trade-down behavior, particularly in the U.S. food can market.
• Silgan differentiates itself through "best-in-class" innovation, deep customer partnerships, and a global low-cost manufacturing footprint.
• The company maintains market share by securing new product launches rather than competing solely on shelf-ready pricing.
• Brazil market experienced negative volume impacts in Q3 and Q4 2026, with recovery expected to begin late 2026 and continue into 2027.

Risks and Challenges:

• Inflation: Resin prices increased over 50% and steel/aluminum costs rose; while pass-throughs exist, there are lags in recovery, particularly in the dispensing segment where non-contractual inflation required aggressive pricing actions.
• Consumer Demand: Weaker-than-anticipated volumes in soup markets and general food/beverage sectors due to consumers stretching dollars.
• Geopolitical/Macro: Unplanned conflicts (e.g., Middle East) and currency headwinds impacted the year, though results remained strong.
• Integration: The Trivium acquisition will require incremental capital investment and operational adjustments to set up the new business structures for success.

Management Commentary and Tone:

• Tone was confident and resilient, emphasizing the team's ability to outpace end markets despite a muted consumer environment.
• Management expressed pride in increasing full-year guidance twice in a challenging year, highlighting execution and strategic agility.
• Confirmed that the fundamental strategy regarding market growth, capital deployment, and customer partnerships remains unchanged despite the upcoming restructuring.
• CEO Adam Greenlee emphasized that the new structure will better position businesses to execute strategic priorities and drive shareholder value.

Analyst Questions and Answers:

• DSC Margins: Management expects DSC margins to normalize and organic EBIT to grow year-over-year in Q4 2026 as inflation pass-throughs catch up.
• Pharma Growth: The pharma segment is a $250M business with 3-5 year regulatory pipelines; growth is driven by innovation, not price competition.
• Volume Outlook: Flat volume expectations for 2026 are driven by softness in soup and F&B, offset by strength in fragrance and pharma; Q4 volumes expected to be comparable to prior year.
• Brazil: Market recovery is delayed; negative impact absorbed in 2026, with growth story shifting to 2027.
• Free Cash Flow 2027: Expectation is for modest free cash flow growth driven by volume recovery and working capital initiatives.
• Trivium Investment: Incremental investments prior to closing will be primarily capital expenditures to prepare facilities and teams, not significant earnings expenses.
• Custom Containers Steady State: Post-footprint optimization, the business is entering a steady state with potential for future growth at current margin rates.

Other Key Points:

• Corporate expenses were approximately $6 million below prior year levels due to the reversal of development costs related to the Trivium announcement.
• Interest expense was favorable due to active treasury management and cash repatriation efforts.
• The company plans to exit lower-margin business in Custom Containers to improve overall mix and cost structure, a process expected to cycle off in Q4 2026.
• Management noted that the new Dispensing Solutions segment will highlight growth in fragrance and pharma more clearly by isolating them from the slower-growing F&B segments in the future MCC structure.